Hypogonadism, male
disease diseaseOn this page
Summary
Hypogonadism, male (MONDO:0009421) is a disease and 46 clinical trials. Top therapeutic interventions include testosterone, testosterone undecanoate, and clomiphene. A subtype of hypogonadism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 46
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hypogonadism, male |
| Mondo ID | MONDO:0009421 |
| OMIM | 241100 |
| SNOMED CT | 48723006 |
| UMLS | C0151721 |
| MedGen | 57480 |
| Is cancer (heuristic) | no |
Also known as: hypogonadism, male
Disease family
This is a subtype of hypogonadism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › gonadal disorder › hypogonadism › hypogonadism, male
Related subtypes (5): gonadal dysgenesis, eunuchism, hypogonadotropic hypogonadism, Slti-Salem syndrome, weinstein kliman scully syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 46.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE4 | 13 |
| PHASE2 | 7 |
| PHASE3 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03851627 | PHASE4 | RECRUITING | Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism |
| NCT07278362 | PHASE4 | NOT_YET_RECRUITING | Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance |
| NCT07328542 | PHASE4 | NOT_YET_RECRUITING | Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men |
| NCT03091348 | PHASE4 | COMPLETED | Subcutaneous vs. Intramuscular Testosterone |
| NCT03176537 | PHASE4 | WITHDRAWN | Periodontal Profile of Hypogonadic Men |
| NCT03203681 | PHASE4 | COMPLETED | Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters |
| NCT03792321 | PHASE4 | COMPLETED | Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients (SETH2) |
| NCT04439799 | PHASE4 | COMPLETED | A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections |
| NCT04456296 | PHASE4 | COMPLETED | A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism |
| NCT04558567 | PHASE4 | COMPLETED | Vogelxo(R) ABPM Study in Hypogandal Men |
| NCT05205837 | PHASE4 | TERMINATED | A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial |
| NCT05381831 | PHASE4 | COMPLETED | Natesto Spermatogenesis Reboot |
| NCT05806723 | PHASE4 | COMPLETED | Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men |
| NCT06689085 | PHASE3 | RECRUITING | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism |
| NCT03198728 | PHASE3 | COMPLETED | Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men |
| NCT03242408 | PHASE3 | COMPLETED | Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) |
| NCT03242590 | PHASE3 | COMPLETED | Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). |
| NCT03868059 | PHASE3 | COMPLETED | Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men |
| NCT04467697 | PHASE3 | COMPLETED | Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men |
| NCT04049331 | PHASE2 | ACTIVE_NOT_RECRUITING | Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone |
| NCT04301765 | PHASE2 | RECRUITING | Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency |
| NCT04798469 | PHASE2 | RECRUITING | Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism |
| NCT05249634 | PHASE2 | RECRUITING | Testosterone Treatment in Men With Chronic Kidney Disease |
| NCT07287800 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation |
| NCT00398580 | PHASE2 | COMPLETED | 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men |
| NCT01904734 | PHASE2 | COMPLETED | Clomid in Men With Low Testosterone With and Without Prior Treatment |
| NCT03335254 | PHASE1/PHASE2 | TERMINATED | A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males |
| NCT03933618 | PHASE2 | COMPLETED | Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function |
| NCT06312761 | PHASE1/PHASE2 | UNKNOWN | Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 |
| NCT00400335 | PHASE1 | COMPLETED | Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride |
| NCT03973840 | PHASE1 | COMPLETED | Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes |
| NCT04717362 | EARLY_PHASE1 | WITHDRAWN | The Effects of Natesto For Treatment Of Hypogonadism |
| NCT06532149 | Not specified | RECRUITING | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
| NCT06720597 | Not specified | RECRUITING | EndoPAT Device for Endothelial Dysfunction in ED |
| NCT06841328 | Not specified | RECRUITING | Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes |
| NCT03254641 | Not specified | COMPLETED | Calciotropic Effects After HCG Stimulation Test |
| NCT03282682 | Not specified | COMPLETED | Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male |
| NCT03541395 | Not specified | COMPLETED | Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males |
| NCT03747003 | Not specified | COMPLETED | Gonadal Function in Young to Middle Aged HIV-infected Men |
| NCT04326673 | Not specified | COMPLETED | Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TESTOSTERONE | 4 | 11 |
| TESTOSTERONE UNDECANOATE | 4 | 7 |
| CLOMIPHENE | 4 | 3 |
| DUTASTERIDE | 4 | 2 |
| GONADORELIN ACETATE | 4 | 2 |
| TESTOSTERONE CYPIONATE | 4 | 2 |
| ALECTINIB | 4 | 1 |
| BRIGATINIB | 4 | 1 |
| GONADOTROPIN, CHORIONIC | 4 | 1 |
| LETROZOLE | 4 | 1 |
| LORLATINIB | 4 | 1 |
| SELPERCATINIB | 4 | 1 |
| SOTORASIB | 4 | 1 |
| TESTOSTERONE ENANTHATE | 4 | 1 |
| ENCLOMIPHENE | 3 | 2 |
| CURCUMIN | 3 | 1 |
| CHEMBL4746472 | 0 | 4 |
| CHEMBL2370644 | 0 | 2 |
| CHEMBL3397300 | 0 | 1 |
| CHEMBL4303155 | 0 | 1 |
| CHEMBL4436406 | 0 | 1 |
| CHEMBL5174767 | 0 | 1 |
| CHEMBL5289235 | 0 | 1 |
| CHEMBL5430810 | 0 | 1 |
| CHEMBL6175025 | 0 | 1 |